A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients

A Cross-sectional Analysis of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01548716

Enrollment

Registered

2012-03-08

Start date

2011-09-30

Completion date

2012-02-29

Last updated

2012-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease, Vitamin D Deficiency

Keywords

Pruritis in hemodialysis patients, 25-Vitamin D in chronic kidney disease

Brief summary

Hypothesis: 25-hydroxy vitamin D levels in non-itching hemodialysis (HD) patients will be higher than those in HD patients with itching 25-hydroxy vitamin D levels will be measured in non-itching hemodialysis patients and compared to levels previously measured in a previous study of 25-hydroxy vitamin D levels of patients complaining of itching.

Detailed description

25-hydroxy vitamin D levels from non-itching HD patients in this study will be compared to 25-hydroxy vitamin D levels from our ongoing study in HD patients with itching. The primary endpoints for both studies are continuous variables. Student's t test will be used to test for statistical significance. Multiple regression analysis will be used for controlling covariates and testing the interaction among covariates.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Hemodialysis treatment for \> 3 months No complaints of itching within 1 month prior to study enrollment

Exclusion criteria

* Age \< 18 years * Failure to provide informed consent * Intact PTH \< 70 pg/ml or \> 1,000 pg/ml * Serum phosphorus \> 7.0 * Serum calcium (adjusted for albumin)\> 11 * Active malignancy * Likelihood of imminent renal transplantation * Current ergocalciferol treatment

Design outcomes

Primary

Measure	Time frame	Description
25 hydroxy vitamin D level	up to 2 weeks	Pt will have blood sample taken and fill out 1) Pruritis Survey 2) Phosphorus Restriction Compliance Survey

Countries

United States

Outcome results